BIOHIT Helicobacter pylori UFT300

Test and report at the same time

BIOHIT H. pylori UFT300 is an ultra-fast rapid urease test that has revolutionised the way H. pylori infection is diagnosed and reported in gastroscopy.

The biopsy taken during gastroscopy can be tested immediately to diagnose H. pylori infection. The test results are ready in only 5 minutes enabling diagnosis and reporting at the same time. This saves the patient from an unnecessary visit to the doctor for hearing the test results. BIOHIT H. pylori UFT300 quick test has excellent sensitivity and specificity which makes it a highly reliable and accurate tool for diagnostics.

BIOHIT H. pylori UFT300 key features:

Ready-to-use rapid test kit
Cup and plate versions available in kit sizes of 5, 50 or 100 tests
Results ready in 5 min (both positive and negative)
Storage in room temperature (18…25 ^oC)
Sensitivity 94,5 %, Specificity 100 %
Testing and reporting during one appointment

This test kit can be complemented with a positive urease control BIOHIT H. pylori Control, which allows daily verification of the performance of the BIOHIT H. pylori UFT300 rapid test prior to testing patient samples.

Helicobacter pylori infection is the most important cause of chronic gastritis. Another mechanism for gastritis and severe atrophic gastritis is the autoimmune mechanism, which can also be triggered by an H. pylori infection. This kit is intended to aid in the diagnosis of H. pylori infection.

Helicobacter pylori is a spiral shaped, gram-negative bacterium that colonizes the human stomach. The organism is found in the mucous layer of the stomach overlying the gastric epithelium and it does not appear to invade tissue. However, the mucosa underneath the area of the H. pylori colonization is invariably inflamed; this condition is referred to as chronic superficial or non-atrophic gastritis, which, if untreated, persists for life. Nevertheless, the chronic inflammatory process can lead to atrophic gastritis, which has been linked with peptic ulceration and gastric cancer, two of the most important diseases of the upper gastrointestinal tract. It is estimated that more than 40% of the adult population of the world is still infected with H. pylori.

The epidemiological evidence of a link between H. pylori infection and gastric adenocarcinoma or mucosa associated lymphoid tissue (MALT) lymphoma has resulted in classification of the organism as a group I carcinogen.